Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.25 +4.9%	$0.27	$0.20 ▼ $1.48	$63.90M	2.18	1.64 million shs	338,557 shs
LPCN Lipocine	$3.14 +1.0%	$3.31	$2.68 ▼ $7.90	$16.64M	1.3	32,928 shs	26,120 shs
PYRGF PyroGenesis Canada	$0.35 -2.5%	$0.34	$0.30 ▼ $0.80	$64.48M	0.84	11,194 shs	7,332 shs
VRCA Verrica Pharmaceuticals	$0.86 +3.8%	$0.58	$0.38 ▼ $8.98	$76.77M	1.76	621,491 shs	522,931 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-3.94%	+0.58%	-14.81%	+6.87%	-80.24%
LPCN Lipocine	-4.89%	-1.58%	-0.96%	+9.89%	-57.34%
PYRGF PyroGenesis Canada	+3.96%	+7.39%	-3.98%	+7.49%	-38.69%
VRCA Verrica Pharmaceuticals	+20.64%	+56.57%	+35.71%	+43.25%	-89.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.1081 of 5 stars	3.1	5.0	0.0	1.3	0.8	0.0
LPCN Lipocine	1.5813 of 5 stars	3.5	3.0	0.0	0.0	0.0	0.6
PYRGF PyroGenesis Canada	0.1035 of 5 stars	0.0	2.0	0.0	0.0	1.7	0.0
VRCA Verrica Pharmaceuticals	3.6231 of 5 stars	3.1	1.0	4.7	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.29	Hold	$1.35	434.26% Upside
LPCN Lipocine	3.00	Buy	$9.00	186.62% Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	2.20	Hold	$8.00	828.18% Upside

Current Analyst Ratings Breakdown

Latest LPCN, ADAP, PYRGF, and VRCA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/14/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/9/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/8/2025	VRCA Verrica Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.38	N/A	N/A	$0.05 per share	5.06
LPCN Lipocine	$11.20M	1.50	N/A	N/A	$3.93 per share	0.80
PYRGF PyroGenesis Canada	$9.14M	7.05	N/A	N/A	($0.01) per share	-34.54
VRCA Verrica Pharmaceuticals	$7.57M	10.53	N/A	N/A	($0.11) per share	-7.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	0.00	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
LPCN Lipocine	$10K	-$1.02	0.00	∞	N/A	N/A	-26.68%	-24.77%	8/6/2025 (Estimated)
PYRGF PyroGenesis Canada	-$21.12M	-$0.02	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A
VRCA Verrica Pharmaceuticals	-$76.58M	-$1.20	0.00	N/A	N/A	N/A	N/A	-145.63%	8/13/2025 (Estimated)

Latest LPCN, ADAP, PYRGF, and VRCA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/13/2025	Q1 2025	VRCA Verrica Pharmaceuticals	-$0.14	-$0.10	+$0.04	-$0.10	$2.53 million	$3.44 million
5/8/2025	Q4 2024	LPCN Lipocine	-$0.35	-$0.35	N/A	-$0.35	$0.35 million	$0.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
LPCN Lipocine	N/A	15.64	15.64
PYRGF PyroGenesis Canada	N/A	0.60	0.50
VRCA Verrica Pharmaceuticals	N/A	1.34	1.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
LPCN Lipocine	9.11%
PYRGF PyroGenesis Canada	0.03%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
LPCN Lipocine	6.35%
PYRGF PyroGenesis Canada	47.68%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	232.08 million	Optionable
LPCN Lipocine	10	5.35 million	5.01 million	No Data
PYRGF PyroGenesis Canada	90	186.69 million	96.34 million	No Data
VRCA Verrica Pharmaceuticals	40	92.49 million	42.55 million	Optionable

LPCN, ADAP, PYRGF, and VRCA Headlines

Recent News About These Companies

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

July 1, 2025 | globenewswire.com

Verrica Shareholder Sues Board Over FDA Approval Hurdle Claims

June 27, 2025 | news.bloomberglaw.comN

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest

June 18, 2025 | marketbeat.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Brokerages

June 16, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% - Here's Why

June 10, 2025 | marketbeat.com

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 28, 2025 | globenewswire.com

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline

May 18, 2025 | msn.com

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call

May 13, 2025 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025 | globenewswire.com

6VRCA : Earnings Outlook For Verrica Pharmaceuticals

May 13, 2025 | benzinga.com

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update

May 11, 2025 | msn.com

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

May 7, 2025 | globenewswire.com

Verrica Pharmaceuticals CEO to Present at Citizens Life Sciences Conference

May 4, 2025 | msn.com

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

April 30, 2025 | globenewswire.com

Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%

April 9, 2025 | aaii.comA

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH

April 9, 2025 | msn.com

In face of U.S. stock market selloff, shares of West Chester firm are on the rise

April 8, 2025 | bizjournals.com

Verrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1

April 8, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

April 7, 2025 | markets.businessinsider.com

RBC Capital Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)

April 5, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN, ADAP, PYRGF, and VRCA Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.25 +0.01 (+4.94%)

Closing price 04:00 PM Eastern

Extended Trading

$0.25 +0.00 (+0.40%)

As of 07:49 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Lipocine NASDAQ:LPCN

$3.14 +0.03 (+0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$3.16 +0.02 (+0.80%)

As of 07:32 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

PyroGenesis Canada NASDAQ:PYRGF

$0.35 -0.01 (-2.54%)

As of 03:00 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

Verrica Pharmaceuticals NASDAQ:VRCA

$0.86 +0.03 (+3.84%)

Closing price 04:00 PM Eastern

Extended Trading

$0.84 -0.03 (-3.12%)

As of 07:31 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time